AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Depression: Clorgyline hydrochloride is used in the management of depression, particularly in cases where other antidepressant medications have been ineffective or poorly tolerated. It works by inhibiting the enzyme monoamine oxidase (MAO), which is responsible for the breakdown of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain. By inhibiting MAO, clorgyline hydrochloride increases the levels of these neurotransmitters in the brain, which may help alleviate depressive symptoms such as low mood, loss of interest or pleasure, fatigue, and changes in appetite or sleep patterns.
Monoamine Oxidase Inhibition: Clorgyline hydrochloride selectively inhibits the activity of MAO type A (MAO-A), which primarily metabolizes serotonin and norepinephrine. By inhibiting MAO-A, clorgyline hydrochloride increases the availability of serotonin and norepinephrine in the synaptic clefts of neurons, thereby enhancing neurotransmission and mood regulation. This mechanism of action is similar to other MAOIs used in the treatment of depression.
Clinical Efficacy: Clorgyline hydrochloride has demonstrated efficacy in the treatment of depression, particularly in clinical trials and studies involving patients with major depressive disorder (MDD) or other mood disorders. It may be used as monotherapy or in combination with other antidepressant medications, depending on the severity and nature of the depressive symptoms. However, due to the risk of potentially serious side effects and drug interactions associated with MAOIs, clorgyline hydrochloride is generally reserved for use in treatment-resistant cases or when other treatment options have been exhausted.
Side Effects: Clorgyline hydrochloride may be associated with a range of potential side effects, some of which can be serious or life-threatening. Common side effects may include dizziness, drowsiness, insomnia, headache, gastrointestinal upset, dry mouth, and changes in appetite or weight. More serious side effects may include hypertensive crisis (dangerously high blood pressure), serotonin syndrome (a potentially life-threatening condition characterized by agitation, confusion, rapid heartbeat, and elevated body temperature), and interactions with certain foods or medications containing tyramine or sympathomimetic agents.
Drug Interactions: Clorgyline hydrochloride has a high potential for drug interactions, particularly with other medications that affect serotonin or norepinephrine levels, such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), sympathomimetic agents, and certain opioids. Concomitant use of clorgyline hydrochloride with these medications may increase the risk of serotonin syndrome or hypertensive crisis, which can be life-threatening.
Contraindications and Precautions: Clorgyline hydrochloride is contraindicated in individuals with known hypersensitivity to MAOIs or any of their components. It should not be used concomitantly with other MAOIs or within 14 days of discontinuing treatment with serotonergic medications or other drugs that increase serotonin levels. Clorgyline hydrochloride should be used with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, or seizure disorders, as it may exacerbate these conditions or increase the risk of adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 3.4 | 0.5 | 5.8 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.5 | 1.5 | -2 |
Allergies | 3.6 | 2.2 | 0.64 |
Allergy to milk products | 0.6 | 0.4 | 0.5 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 2.4 | 3.4 | -0.42 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 1.3 | 1.23 |
Ankylosing spondylitis | 2.1 | 1.2 | 0.75 |
Anorexia Nervosa | 0 | 1.6 | 0 |
Antiphospholipid syndrome (APS) | 1 | 1 | |
Asthma | 1.1 | 1.5 | -0.36 |
Atherosclerosis | 1.1 | 1.1 | 0 |
Atrial fibrillation | 2.7 | 0.7 | 2.86 |
Autism | 6.7 | 6.7 | 0 |
Barrett esophagus cancer | 0.6 | 0.2 | 2 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.5 | 1.2 | -1.4 |
Brain Trauma | 0.6 | 0.2 | 2 |
Carcinoma | 2.5 | 1.9 | 0.32 |
Celiac Disease | 1.1 | 3.6 | -2.27 |
Cerebral Palsy | 1.5 | 0.9 | 0.67 |
Chronic Fatigue Syndrome | 4.1 | 3.4 | 0.21 |
Chronic Kidney Disease | 1.2 | 1.3 | -0.08 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 0.5 | 2.6 |
Chronic Urticaria (Hives) | 0.8 | 1.1 | -0.38 |
Coagulation / Micro clot triggering bacteria | 0.3 | 1 | -2.33 |
Colorectal Cancer | 2.1 | 0.8 | 1.63 |
Constipation | 0.6 | 0.5 | 0.2 |
Coronary artery disease | 1 | 1 | 0 |
COVID-19 | 9.5 | 10.5 | -0.11 |
Crohn's Disease | 4.4 | 4.2 | 0.05 |
cystic fibrosis | 0.1 | 0.5 | -4 |
deep vein thrombosis | 0.1 | 0.5 | -4 |
Depression | 6.5 | 6.6 | -0.02 |
Dermatomyositis | 0.2 | 0.3 | -0.5 |
Eczema | 0.6 | 1.1 | -0.83 |
Endometriosis | 1.5 | 1.3 | 0.15 |
Eosinophilic Esophagitis | 0.2 | 0.4 | -1 |
Epilepsy | 2.2 | 2.4 | -0.09 |
Fibromyalgia | 1.2 | 1.2 | 0 |
Functional constipation / chronic idiopathic constipation | 3.1 | 1.6 | 0.94 |
gallstone disease (gsd) | 1.4 | 0.5 | 1.8 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1.2 | -0.71 |
Generalized anxiety disorder | 0.9 | 1.6 | -0.78 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.8 | 0.9 | -0.13 |
Halitosis | 0.7 | 0.2 | 2.5 |
Hashimoto's thyroiditis | 2 | 0.5 | 3 |
Hidradenitis Suppurativa | 0.4 | 0.4 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2 | 0.8 | 1.5 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.9 | -1.25 |
hyperglycemia | 0 | 2.3 | 0 |
Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 1.8 | 2.9 | -0.61 |
Hypothyroidism | 1.3 | -1.3 | |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 3.1 | -3.1 | |
Inflammatory Bowel Disease | 2.5 | 6.2 | -1.48 |
Insomnia | 0.8 | 0.5 | 0.6 |
Intelligence | 0.4 | 0.2 | 1 |
Intracranial aneurysms | 0.9 | 0.3 | 2 |
Irritable Bowel Syndrome | 3.1 | 3.1 | 0 |
Liver Cirrhosis | 3.2 | 2.2 | 0.45 |
Long COVID | 5.9 | 7.6 | -0.29 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.1 | 1.8 | -17 |
ME/CFS with IBS | 0.7 | 1.9 | -1.71 |
ME/CFS without IBS | 1.7 | 0.8 | 1.13 |
Menopause | 2 | 2 | |
Metabolic Syndrome | 4.4 | 5.4 | -0.23 |
Mood Disorders | 9.2 | 7 | 0.31 |
multiple chemical sensitivity [MCS] | 1.5 | 0.5 | 2 |
Multiple Sclerosis | 5.8 | 2.5 | 1.32 |
Multiple system atrophy (MSA) | 1.9 | 1.1 | 0.73 |
Neuropathy (all types) | 1.2 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | 5.5 | -2.67 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 4.8 | 4.3 | 0.12 |
obsessive-compulsive disorder | 4.3 | 3.4 | 0.26 |
Osteoarthritis | 1.2 | 0.3 | 3 |
Osteoporosis | 1.3 | 1.5 | -0.15 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.8 | 2.3 | 0.22 |
Polycystic ovary syndrome | 1.2 | 1.7 | -0.42 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.5 | -4 |
Premenstrual dysphoric disorder | 1.1 | 0 | 0 |
primary biliary cholangitis | 0.1 | 0.4 | -3 |
Psoriasis | 3.2 | 1.5 | 1.13 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.7 | 2 | 1.35 |
Rosacea | 1.1 | 0.1 | 10 |
Schizophrenia | 5.6 | 1.4 | 3 |
scoliosis | 0.2 | 1 | -4 |
Sjögren syndrome | 2.3 | 1.7 | 0.35 |
Sleep Apnea | 1.4 | 1.1 | 0.27 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.9 | -0.8 |
Stress / posttraumatic stress disorder | 1.4 | 2.5 | -0.79 |
Systemic Lupus Erythematosus | 2.4 | 1.7 | 0.41 |
Tic Disorder | 0.6 | 0.9 | -0.5 |
Tourette syndrome | 0.5 | 0.2 | 1.5 |
Type 1 Diabetes | 2.4 | 1.2 | 1 |
Type 2 Diabetes | 4.4 | 4.7 | -0.07 |
Ulcerative colitis | 1.6 | 3.6 | -1.25 |
Unhealthy Ageing | 3.5 | 1.6 | 1.19 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.